CDA Essentials 2016 • Volume 3 • Issue 7 - page 38

38
|
Volume3 Issue7
S
upporting
Y
our
P
ractice
Needexpertadvice?
Sendusyourclinicalquestions.
or
1-855-71-OASIS
References
1. AmericanDentalAssociation.StatementonHumanPapillomavirus
andSquamousCellCancersoftheOropharynx.Chicago(IL):ADA.
Available:ada.org/en/about-the-ada/ada-positions-policies-and-
statements/statement-on-human-papillomavirus-and-squamous-
cel(accessed2015Sept25).
2. ClevelandJL,JungerML,SaraiyaM,MarkowitzLE,DunneEF,
EpsteinJB.Theconnectionbetweenhumanpapillomavirusand
oropharyngealsquamouscellcarcinomas intheUnitedStates:
Implications fordentistry.JAmDentAssoc.2011;142;915-924.
3. PublicHealthAgencyofCanada.Canadian ImmunizationGuide,
Part4–ActiveVaccines,HumanPapillomavirusVaccine.Ottawa
(ON):PHAC.Available:phac-aspc.gc.ca/publicat/cig-gci/p04-hpv-
vph-eng.php(accessed2015Sept25).
4. Centers forDiseaseControlandPrevention.HumanPapillomavirus
(HPV),GentitalHPV Infection–FactSheet.Atlanta(GA):CDC.
Available:www.cancer.ca/en/cancer-information/cancer-101/what-
is-a-risk-factor/viruses-bacteria-and-other-infectious-agents/
hpv/?region=on#HPV_and_cancer(accessed2016July25).
THEAUTHORS
Dr.NitaMazurat
Dr.Mazurat is anassociate
professor in the department
of restorative dentistryand
the director of infection
preventionand control for
the college of dentistryat the
University ofManitoba.
She is also the primary
author of theManitoba
DentalAssociation infection
preventionand control
guidelines.
Dr.SuhamAlexander
Dr.Alexander is in private
practice in theOttawaarea
and is clinical editor ofOasis
Discussions atCDA.
Key information aboutHPV from theCanadian
ImmunizationGuide
3
in their lives. Generally, HPV
resolveson itsownbut if it does
not resolve it cancausehealth
problems, includingcancer. The
dental team shouldencourage
adultpatients todiscuss theHPV
vaccinewith their physicianas
apreventivehealthmeasure for
themselves and their children.
InCanada
4
, it is estimated that
HPV is associatedwith80–90%
of anal cancers, 40–50%of penile
cancers, 40%of vaginal andvul-
var cancers, 25–35%of oral cavity
andoropharyngeal cancers.Most
of thesecancers areattributed to
high-riskHPV types 16and18.
a
To read the fullOasis
Discussionspost, pleasevisit:
What
• HPV infectionsare themost commonsexually transmitted
infections.MostHPV infectionsoccurwithout symptomsand
resolvewithout treatment.
• Ifnot immunized,most sexuallyactiveCanadianswillhavean
asymptomaticHPV infectionat some time.
• High-riskHPV types16and18andotherscan lead tocervical and
anogenital cancers, aswell ascertaincancersof theheadandneck.
• Low-riskHPV types6and11cancausegenitalwarts.
• HPV2andHPV4vaccinesprotectagainst cervical cancer.HPV4
vaccinealsoprotectsagainstgenitalwarts.
Who
• HPV2orHPV4vaccine is recommended forpreventionofcervical
cancer ingirlsandwomen9 to26yearsof age, including thosewho
havehadpreviousPap testabnormalities, cervical cancerorgenital
warts.
• HPV4vaccine is recommended for thepreventionof vulvar, vaginal,
anal cancersand theirprecursorsandanogenitalwarts ingirlsand
women, 9-26yearsof age.
• HPV2orHPV4vaccinemaybeadministered towomen27yearsof
ageandolderatongoing riskofexposure.
• HPV4vaccine is recommended forpreventionof anogenital cancer
andgenitalwarts inboysandmen9 to26yearsof age.
• HPV4vaccinemaybeadministered tomen27yearsofageandolder
atongoing riskof exposure.HPV2vaccine isnot approved foruse in
boysandmen.
1...,28,29,30,31,32,33,34,35,36,37 39,40,41,42,43,44,45,46,47,...48
Powered by FlippingBook